The Incretin Effect Explained: GLP-1, GIP & Why It Matters

Here is a fact that sounds impossible the first time you hear it: if you swallow a measured dose of glucose, your body releases far more insulin than if a doctor drips the exact same amount of glucose straight into your vein to produce the identical blood-sugar curve. Same glucose, same blood levels, very different insulin response. That gap is the incretin effect — and it is the single piece of biology that explains why Ozempic, Wegovy, Mounjaro, Zepbound and the whole class of GLP-1 medications exist. The extra insulin comes from gut hormones, chiefly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), that your intestine releases when food arrives and that tell the pancreas a meal is coming. In healthy people these two hormones account for roughly 50 to 70 percent of the insulin your body makes after eating (Nauck 2018 ^[1]). This article explains what the incretin effect actually is, what GLP-1 and GIP each do, why it breaks down in type 2 diabetes, and how that biology became a drug.

The honest summary

• The incretin effect is the insulin "bonus" from eating. Oral glucose produces a much bigger insulin response than intravenous glucose matched to the same blood-sugar levels. The difference is caused by gut hormones released when nutrients hit the intestine (Nauck 1986 ^[3]).
• Two hormones do most of the work: GLP-1 and GIP. Together they are responsible for an estimated 50 to 70 percent of meal-stimulated insulin secretion in healthy people (Nauck 2018 ^[1]; Holst 2007 ^[2]).
• It is glucose-dependent. GLP-1 and GIP amplify insulin release mainly when blood sugar is elevated. When glucose is normal or low, the signal switches off — which is the core reason GLP-1 drugs carry a low risk of hypoglycemia on their own (Drucker 2018 ^[8]).
• In type 2 diabetes the incretin effect is sharply reduced. A meta-analysis confirms the incretin effect is consistently diminished in type 2 diabetes, often contributing less than 20 to 30 percent of the post-meal insulin response instead of the usual majority (Grespan 2022 ^[5]).
• GLP-1 still works in diabetes; GIP largely stops working. A classic experiment showed that infusing GLP-1 still drove insulin and lowered glucose in people with type 2 diabetes, while GIP had lost most of its effect — which is why drug developers built around GLP-1 first (Nauck 1993 ^[4]).
• This is the blueprint for the drugs. GLP-1 receptor agonists are engineered, long-lasting versions of the natural hormone. Tirzepatide goes further as a dual GIP and GLP-1 receptor agonist, and outperformed a GLP-1-only drug head-to-head (Willard 2020 ^[9]; Frias 2021 ^[10]).

The experiment that defines the incretin effect

The cleanest way to see the incretin effect is a paired experiment that researchers have run for decades. On one day, a volunteer drinks a known amount of glucose and the team measures the blood-sugar curve and the insulin response. On a second day, the same person receives glucose intravenously — but the infusion is carefully titrated to reproduce the identical blood-glucose curve from the oral day (an "isoglycemic" infusion). Because the blood sugar is matched minute-by-minute, any difference in insulin can only come from the route. The oral route wins every time: it produces a much larger insulin response, frequently two to three times higher than the IV route at the same glycemia (Nauck 2018 ^[1]; Holst 2007 ^[2]).

The explanation is anatomical. When glucose and other nutrients are infused into a vein, they bypass the gut entirely. When they pass through the intestine, they trigger specialized hormone-secreting cells in the gut wall — the L cells and K cells — to release GLP-1 and GIP into the bloodstream. Those hormones reach the pancreas and prime the insulin-producing beta cells to respond more vigorously to the rising glucose. So the body is not just reacting to the sugar in the blood; it is getting an advance warning from the gut that a nutrient load is on the way. That advance warning is the incretin effect.

What GLP-1 and GIP each actually do

Both hormones share the headline job — they potentiate glucose-stimulated insulin secretion — but they are released from different cells and have distinct secondary effects. GIP is secreted by K cells, concentrated in the upper small intestine, and is released quickly after a meal. GLP-1 is secreted by L cells, more abundant further down the gut, and beyond boosting insulin it does several things GIP does not: it suppresses glucagon (the hormone that raises blood sugar), slows gastric emptying so food and glucose enter the bloodstream more gradually, and acts on appetite centers in the brain to increase fullness and reduce food intake (Holst 2007 ^[2]; Drucker 2018 ^[8]).

That broader profile of GLP-1 — insulin up, glucagon down, stomach slower, appetite reduced — is exactly why a GLP-1 receptor agonist is useful for both blood sugar and weight, not just glucose control. GIP's role in body weight is more nuanced and was historically less clear, which is part of why the first generation of incretin drugs targeted GLP-1 alone before dual agonists arrived (Drucker 2018 ^[8]; Willard 2020 ^[9]).

Why the hypoglycemia risk is low: glucose-dependence

A crucial and often-misunderstood feature is that the incretin amplification of insulin is glucose-dependent. GLP-1 and GIP enhance insulin secretion mainly when blood glucose is elevated; as glucose falls back toward normal, the insulin-stimulating signal fades. In other words, these hormones turn up the volume on insulin only when there is sugar to clear. This is fundamentally different from injected insulin or from sulfonylurea drugs, which push insulin out regardless of the current glucose level and can therefore drive blood sugar dangerously low. Because GLP-1 receptor agonists work through this glucose-dependent mechanism, they carry a low intrinsic risk of hypoglycemia when used on their own — though that risk rises if they are combined with insulin or a sulfonylurea (Drucker 2018 ^[8]; Holst 2007 ^[2]). For a deeper look at when low blood sugar can still occur, see GLP-1 and hypoglycemia in people without diabetes.

Why it matters: the broken incretin effect in type 2 diabetes

The reason this biology became a multibillion-dollar drug class is that the incretin effect is impaired in type 2 diabetes. The original observation came from a 1986 paired-infusion study: people with type 2 diabetes showed a markedly smaller insulin "bonus" from oral versus matched intravenous glucose than healthy controls did (Nauck 1986 ^[3]). A 2022 systematic review and meta-analysis confirmed the finding across the literature — the incretin effect is consistently and substantially reduced in type 2 diabetes, so the gut hormones that should supply the majority of post-meal insulin instead contribute far less (Grespan 2022 ^[5]).

An important nuance is whether the diminished incretin effect causes diabetes or is a consequence of it. The evidence leans toward consequence: chronically elevated blood sugar appears to blunt the gut-hormone signaling, and the reduced incretin effect is best understood as a feature of the established diabetic state rather than a primary trigger (Knop 2007 ^[6]). Studies in close relatives of people with type 2 diabetes — who carry elevated genetic risk but normal glucose tolerance — found their incretin hormone secretion and incretin effect were largely intact, supporting the idea that the defect emerges with the disease rather than before it (Nauck 2004 ^[7]).

How the biology became the drugs

Natural GLP-1 is useless as a daily medication for one reason: an enzyme called DPP-4 chops it up within about one to two minutes of release. The pharmaceutical solution was to engineer modified versions of the hormone that resist DPP-4 and last for hours or days — the GLP-1 receptor agonists. Semaglutide (Ozempic, Wegovy, Rybelsus) and liraglutide are built on the human GLP-1 backbone; exenatide was derived from a peptide found in Gila monster venom. All of them work by occupying the same GLP-1 receptor the natural hormone uses, but they stay around long enough to provide a sustained, supra-physiological incretin signal — restoring and amplifying the effect that is deficient in diabetes, and harnessing GLP-1's appetite and gastric-emptying actions for weight loss (Drucker 2018 ^[8]).

The next step was to bring GIP back into the picture. Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is a single engineered molecule that activates both the GIP and GLP-1 receptors — a dual agonist. Detailed pharmacology shows tirzepatide is an "imbalanced" agonist that engages the GIP receptor strongly while activating the GLP-1 receptor with a biased signaling profile (Willard 2020 ^[9]). Even though GIP's natural insulin effect is blunted in diabetes, adding GIP-receptor activation on top of GLP-1 produced better results in practice: in the head-to-head SURPASS-2 trial, tirzepatide lowered HbA1c and body weight more than the GLP-1-only drug semaglutide (Frias 2021 ^[10]). For a closer comparison of the two molecules, see tirzepatide vs semaglutide head-to-head, and for the medical-abbreviation primer see what "GIP receptor" means.

So the entire arc — from a curious 1980s observation that oral glucose beats IV glucose, to a class of drugs that has reshaped diabetes and obesity care — runs through the incretin effect. The drugs do not invent a new pathway; they restore and amplify a normal one that the body uses every time you eat. If you want to see how this gut-hormone signaling shows up in routine lab markers, see GLP-1, fasting insulin and HOMA-IR.

Bottom line

The incretin effect is the extra insulin your body releases when glucose arrives through the gut rather than the vein — driven by the hormones GLP-1 and GIP, which together supply most of your meal-time insulin in good health (Nauck 2018 ^[1]). It is glucose-dependent, which is why the medications built on it rarely cause low blood sugar by themselves (Drucker 2018 ^[8]). In type 2 diabetes this effect is sharply diminished (Grespan 2022 ^[5]), and crucially GLP-1 keeps working while GIP largely stops (Nauck 1993 ^[4]). Drug developers exploited exactly that: GLP-1 receptor agonists are durable, engineered copies of the natural hormone, and tirzepatide reintroduces GIP-receptor activation as a dual agonist that beat a GLP-1-only drug head-to-head (Frias 2021 ^[10]). Understanding the incretin effect is, in the end, understanding why these drugs work at all.

This article is educational and is not medical advice. Every claim above is sourced to a peer-reviewed study, physiology review, or randomized trial indexed in PubMed, verified against the live PubMed database before publication. Discuss any medication decision with a qualified clinician.